ABL1 and cancer: Given the extensive divergence of the numerous BCR-ABL oncogene-independent pathways that are deregulated in LSCs, it is not surprising that cellular metabolic reprogramming (an emerging hallmark for cancer stem-cell biology) [137] has been also implicated in LSC survival adaptations and resistance to TKI treatment.